Diabetes News and Research

Latest Diabetes News and Research

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Nuffield Health Leeds Hospital offers incisionless TOGA Procedure for treatment of obesity

Nuffield Health Leeds Hospital announced today that it will be the first hospital in the UK to offer the incisionless TOGA® Procedure for treatment of obesity commencing in January 2011. The TOGA Procedure has been used to treat over 450 patients worldwide - its incision-free approach is very minimally invasive and offers the benefits of minimal pain and downtime, and an excellent safety profile.

10 Nov 2010

Repros third quarter net loss decreases to $1.2 million

Repros Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2010 and provided an update on corporate actions.

10 Nov 2010

Psychologists find stress is taking physical and emotional health toll on family and children

Findings from the American Psychological Association's (APA) newly released 2010 Stress in America survey raise red flags about the long-term impact that chronic stress could have on our physical and emotional health and the health of our families, psychologists said today.

10 Nov 2010

Jefferson awarded $2.6M grant for study on cognitive decline in older African Americans with MCI

Researchers in the Departments of Psychiatry and Neurology at Jefferson Medical College of Thomas Jefferson University were recently awarded a $2.6 million grant from The National Institute of Health to study whether increasing participation in cognitive, physical and/or social activities prevents cognitive decline in older African Americans with Mild Cognitive Impairment (MCI).

10 Nov 2010

Researchers study drug's ability to restore retinal health in eyes of diabetic patients

One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.

10 Nov 2010

NHLBI launches new campaign to highlight common COPD symptoms

The number of Americans who report being aware of chronic obstructive pulmonary disease, or COPD, increased by 4 percentage points between 2008 and 2010, but many people at risk are still unaware of the disease, according to mailed survey results released today by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Adolescent obesity associated with risk of severe obesity in adulthood

Obese adolescents are 16 times more likely to become severely obese by age 30 than their healthy weight or even overweight peers, according to a new study from the University of North Carolina at Chapel Hill.

10 Nov 2010

Education can help prevent preterm birth

Doctors and patients should discuss a pregnant woman's risk of preterm birth by the twelfth week of pregnancy, according to a commentary published in the November issue of Ob.Gyn. News.

10 Nov 2010

Diamyd completes patient screening for DiaPrevent Phase III study

Diamyd Medical has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd® or placebo.

10 Nov 2010

Gov't health IT spending attracts investments from all over

As part of its foray into health IT, AT&T has partnered with WellDoc, a Baltimore-based company that makes an FDA-approved mobile-phone application to help manage diabetes, The Baltimore Sun reports. "The telecommunications giant launched a new business segment last week that will focus on technology solutions for the health care industry. And WellDoc's software will be pitched by AT&T's huge marketing muscle to commercial clients ranging from hospitals to insurers to employers" (Sentementes, 11/8).

10 Nov 2010

Stressed out Americans

The American Psychological Association’s (APA) have released the results of the 2010 Stress in America survey that shows up the long-term impact that chronic stress could have on physical and emotional health and the health of the families. The survey was conducted by Harris Interactive in August 2010. It showed some worrying trends of stress among parents as well as children.

9 Nov 2010

Redpoint Bio decreases third quarter net loss to $1.8 million

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the three months and nine months ended September 30, 2010.

9 Nov 2010

Study says looking older does not necessarily point to poor health

Even though most adults want to avoid looking older than their actual age, research led by St. Michael's Hospital shows that looking older does not necessarily point to poor health. The study found that a person needed to look at least 10 years older than their actual age before assumptions about their health could be made.

9 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

March of Dimes honors professor who linked fetal malnutrition to chronic adult disease

The world-renowned physician and professor who pioneered the theory linking fetal malnutrition to chronic adult disease will receive the March of Dimes Agnes Higgins Award for outstanding achievement in the field of maternal-fetal nutrition.

9 Nov 2010

Food insecurity may cause problem for diabetic patients living on fixed incomes

The economic recession impacts many aspects of our lives including an increase incidence of food insecurity. This can have serious consequences for those suffering from chronic illnesses like diabetes.

9 Nov 2010

Endeca, eHealth Ontario partner to implement chronic disease management system

Endeca Technologies, Inc., a search and business intelligence (BI) company, today announced that eHealth Ontario, an agency of the Government of Ontario, has selected Endeca and commenced work on the chronic disease management system (CDMS) and portal project previously announced in August 2010. Endeca, working with its partners, will assist with the design, build, and implementation of the system that will be used initially to better manage diabetes care throughout the province.

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010